A detailed history of Carmichael Hill & Associates, Inc. transactions in Abb Vie Inc. stock. As of the latest transaction made, Carmichael Hill & Associates, Inc. holds 6,760 shares of ABBV stock, worth $1.19 Million. This represents 0.48% of its overall portfolio holdings.

Number of Shares
6,760
Previous 6,689 1.06%
Holding current value
$1.19 Million
Previous $1.15 Million 16.3%
% of portfolio
0.48%
Previous 0.45%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

BUY
$163.84 - $199.33 $11,632 - $14,152
71 Added 1.06%
6,760 $1.33 Million
Q2 2024

Aug 02, 2024

BUY
$154.79 - $180.76 $2,012 - $2,349
13 Added 0.19%
6,689 $1.15 Million
Q1 2024

Apr 24, 2024

BUY
$159.82 - $182.1 $1,917 - $2,185
12 Added 0.18%
6,676 $1.22 Million
Q4 2023

Jan 23, 2024

BUY
$137.6 - $154.97 $1,926 - $2,169
14 Added 0.21%
6,664 $1.03 Million
Q3 2023

Oct 30, 2023

BUY
$133.59 - $154.65 $1,736 - $2,010
13 Added 0.2%
6,650 $991,000
Q2 2023

Aug 04, 2023

BUY
$132.51 - $164.9 $160,734 - $200,023
1,213 Added 22.36%
6,637 $894,000
Q1 2023

Apr 05, 2023

BUY
$144.61 - $166.54 $19,377 - $22,316
134 Added 2.53%
5,424 $864,000
Q4 2022

Feb 13, 2023

SELL
$138.31 - $165.87 $414 - $497
-3 Reduced 0.06%
5,290 $855,000
Q3 2022

Nov 10, 2022

BUY
$134.21 - $153.93 $1,476 - $1,693
11 Added 0.21%
5,293 $710,000
Q2 2022

Aug 05, 2022

SELL
$137.62 - $174.96 $136,381 - $173,385
-991 Reduced 15.8%
5,282 $809,000
Q1 2022

May 16, 2022

BUY
$131.98 - $163.75 $144,386 - $179,142
1,094 Added 21.12%
6,273 $1.02 Million
Q4 2021

Jan 31, 2022

BUY
$107.43 - $135.93 $3,867 - $4,893
36 Added 0.7%
5,179 $701,000
Q3 2021

Nov 12, 2021

BUY
$106.4 - $120.78 $1,276 - $1,449
12 Added 0.23%
5,143 $555,000
Q2 2021

Aug 03, 2021

BUY
$105.21 - $117.21 $2,209 - $2,461
21 Added 0.41%
5,131 $578,000
Q1 2021

Apr 28, 2021

BUY
$102.3 - $112.62 $3,478 - $3,829
34 Added 0.67%
5,110 $553,000
Q4 2020

Jan 27, 2021

BUY
$80.49 - $108.67 $55,860 - $75,416
694 Added 15.84%
5,076 $544,000
Q3 2020

Nov 12, 2020

BUY
$85.91 - $100.83 $22,937 - $26,921
267 Added 6.49%
4,382 $384,000
Q2 2020

Aug 05, 2020

BUY
$73.37 - $98.18 $42,554 - $56,944
580 Added 16.41%
4,115 $404,000
Q1 2020

May 05, 2020

BUY
$64.5 - $97.79 $8,127 - $12,321
126 Added 3.7%
3,535 $269,000
Q4 2019

Jan 30, 2020

SELL
$72.13 - $90.25 $5,265 - $6,588
-73 Reduced 2.1%
3,409 $302,000
Q3 2019

Nov 06, 2019

SELL
$62.98 - $75.72 $20,090 - $24,154
-319 Reduced 8.39%
3,482 $264,000
Q2 2019

Jul 30, 2019

SELL
$65.7 - $83.98 $4,073 - $5,206
-62 Reduced 1.6%
3,801 $276,000
Q1 2019

Apr 23, 2019

SELL
$77.14 - $90.79 $7,482 - $8,806
-97 Reduced 2.45%
3,863 $311,000
Q4 2018

Jan 16, 2019

SELL
$77.85 - $96.01 $8,797 - $10,849
-113 Reduced 2.77%
3,960 $365,000
Q3 2018

Nov 09, 2018

BUY
$88.91 - $98.84 $177 - $197
2 Added 0.05%
4,073 $385,000
Q2 2018

Aug 01, 2018

BUY
$89.78 - $106.23 $179 - $212
2 Added 0.05%
4,071 $377,000
Q1 2018

Apr 27, 2018

BUY
$92.01 - $123.21 $184 - $246
2 Added 0.05%
4,069 $385,000
Q4 2017

Feb 07, 2018

BUY
$89.56 - $98.21 $364,240 - $399,420
4,067
4,067 $393,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $310B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track Carmichael Hill & Associates, Inc. Portfolio

Follow Carmichael Hill & Associates, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Carmichael Hill & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Carmichael Hill & Associates, Inc. with notifications on news.